For the quarter ending 2026-03-31, CTRVP has $2,705,503 in assets. $848,747 in debts.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash | 2,602,580 | 1,828,062 | 2,321,078 | 2,924,395 |
| Prepaid expenses | 102,923 | 1,241,890 | 1,419,162 | 1,581,074 |
| Total current assets | 2,705,503 | 3,069,952 | 3,740,240 | 4,505,469 |
| Total assets | 2,705,503 | 3,069,952 | 3,740,240 | 4,505,469 |
| Accounts payable | 138,442 | 167,810 | 77,243 | 172,698 |
| Notes payable, current | - | 54,066 | 214,309 | 371,661 |
| Accrued expenses | 347,130 | 77,507 | 55,859 | 48,495 |
| Subscription liability | 250,000 | - | - | - |
| Total current liabilities | 735,572 | 299,383 | 347,411 | 592,854 |
| Derivative financial instrumentswarrants | 113,175 | 103,022 | 68,397 | 115,677 |
| Total liabilities | 848,747 | 402,405 | 415,808 | 708,531 |
| Convertible preferred stock-Series APreferred Stock | 855,808 | 855,808 | 855,808 | 855,808 |
| Convertible preferred stock-Series CPreferred Stock | 839,320 | 839,320 | 839,320 | 839,320 |
| Common stock0.0001 par value per share 120,000,000 shares authorized, 11,620,317 issued and outstanding at march 31, 2026 and december 31, 2025 | 1,162 | 1,162 | 1,162 | 1,162 |
| Additional paid-in capital | 247,060,568 | 247,060,568 | 247,060,568 | 247,060,568 |
| Accumulated other comprehensive income | 8,345 | 8,345 | 8,345 | 8,345 |
| Accumulated deficit | -246,908,447 | -246,097,656 | -245,440,771 | -244,968,265 |
| Total stockholders equity | 1,856,756 | 2,667,547 | 3,324,432 | 3,796,938 |
| Total liabilities and stockholders equity | 2,705,503 | 3,069,952 | 3,740,240 | 4,505,469 |
Hepion Pharmaceuticals, Inc. (CTRVP)
Hepion Pharmaceuticals, Inc. (CTRVP)